Patterns of drug resistance mutations after failure of first-line NNRTI-based antiretroviral therapy in Western India by SN Pujari et al.
BioMed Central
Page 1 of 1
(page number not for citation purposes)
Journal of the International AIDS 
Society
Open AccessPoster presentation
Patterns of drug resistance mutations after failure of first-line 
NNRTI-based antiretroviral therapy in Western India
SN Pujari*1, AN Dravid1, N Gupte2, A Makne1, S Gaikwad1, 
P Mukhopadhaya3, B Aich3 and V Bele1
Address: 1Institute of Infectious Diseases, Pune, India, 2Consultant Biostatistician, Pune, India and 3Genomebio Laboratories, Pune, India
* Corresponding author    
Background
There is limited information on the pattern of drug resist-
ance mutations (DRMs) after failure of NNRTI-based first-
line ART in India (subtype C viruses). We assessed the
prevalence of DRMs after first-line failure and explored
risk factors associated with development of thymidine
analog mutations (TAMs).
Methods
Patients with confirmed first-line therapy failure (d4T or
ZDV/3TC/NVP or EFV) as defined virologic (VF), immu-
nologic (IF) and clinical (CF) (according to WHO ARV
scale-up guidelines), were eligible. Genotypic drug resist-
ance testing (GRT) was done by viral RNA extraction, RT-
PCR and in-house sequencing and interpretation done
according to the Stanford database. The frequency of
DRMs (NNRTI mutations-K103N, V106M, Y181C,
G190A and others, 3TC-M184V/I and TAMs: 41, 210, 215
or 67, 70, 219 or no specific pathway) were determined.
Univariate analysis were used to determine the risk of
development of >3 TAMs according to age, gender, type of
failure, duration on regimen, duration of HIV infection,
exposure to suboptimal regimens, CD4 counts and PVL at
time of GRT.
Summary of results
Data from 89 patients (80.6% male) with median age 38
years were available. Median duration on ART at the time
of GRT was 43.5 (IQR 23–67) months, and the median
PVL and CD4 count were 4.5 log copies/ml (IQR 4.1–5.3)
and 168/mm3(IQR 67–289), respectively. 83% patients
had PVL>4 logs. Amongst patients with failure, 42% were
VF, 39.7% IF and 18.3% CF. All patients were infected
with subtype c virus. 92%, 66.6% and 31.1% patients had
NNRTI mutations (K103N:44.4%, Y181C:32.1%),
M184V and both, respectively. At least one TAM was doc-
umented in 71.9% patients, 38.2% had >3 TAMs, with
38.2% and 35.5% following the 67/70/219 and 41/210/
215 pathway. 4.4% had K65R. A last CD4 count<200/
mm3 and PVL >4 log copies/ml were associated with a
trend towards harbouring >3 TAMs, though they failed to
achieve statistical significance.
Conclusion
Patterns of resistance mutations after failure of NNRTI-
based first-line regimens amongst subtype C viruses is
similar to that documented in other subtypes in literature.
After failure of first-line therapy most patients have
NNRTI and/or 3TC resistance. The frequency of TAMs is
high and is associated with high viral loads and low CD4
counts at the time of GRT.
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